Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
X
Youtube
Linkedin
August, 2024
August 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jul
European School of Oncology
Jun 6, 2024, 00:29 |
Blog
Paolo Tarantino: Expansion cohorts from TBCRC by Nadine Tung
Paolo Tarantino shared a post on X: “One of the most important presentations of ASCO24:…
Jun 5, 2024, 09:11 |
Blog
Shushan Hovsepyan: My Poster at the ASCO24
Shushan Hovsepyan shared on LinkedIn: . "My Poster at American Society of Clinical…
Jun 1, 2024, 23:36 |
Blog
Paolo Tarantino: Our article on Optimizing the Safety of ADCs for their Outlook on Cancer treatment has been published in Nature
Paolo Tarantino shared a post on LinkedIn: ''Grateful to Nature for selecting our article on…
Jun 1, 2024, 22:59 |
Blog
Julie Gralow: Don’t miss this joint ASCO - ECO education session at ASCO24
Julie Gralow shared on LinkedIn: . "Don’t miss this joint American…
Jun 1, 2024, 20:58 |
Dialogues
Oncothon: Pediatric Cancer Research with Ricardo Garcia and Ben Rayner
Oncothon is a telethon spanning 24 hours, dedicated to gathering donations for childhood cancer research.…
May 31, 2024, 07:46 |
Blog
Shushan Hovsepyan: Sarcoma Sessions at ASCO2024!
Shushan Hovsepyan shared a post on LinkedIn: “Sarcoma Sessions at ASCO2024! SARC037: Phase II results…
May 29, 2024, 08:20 |
Blog
Paolo Tarantino: In this work by the AZ translational team, QCS proved superior to manual IHC in predicting the activity of T-DXd
Paolo Tarantino shared a post on X: "In the ph1 trial of T-DXd in HER2-low MBC,…
May 28, 2024, 14:34 |
Drugs
Paolo Tarantino: Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer
Paolo Tarantino shared on X: "Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer.…
May 28, 2024, 08:05 |
Insight
Sylvester Research Shows New Treatment May Enable More Patients With High-Risk Blood Cancers to Receive Stem Cell Transplants
Patients from underrepresented racial and ethnic groups stand to benefit the most, which is particularly…
May 28, 2024, 04:25 |
Insight
Arndt Vogel: A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Arndt Vogel shared on X: “A randomized phase II trial of Captem or Folfiri as…
19
20
21
22
23
All:
270
Posts:
201 - 210
How The Breast Cancer Research Foundation was founded
Can Skin Cancer be Prevented by a $0.50 Soap? Meet TIME’s Kid of the Year and His Invention
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024
Uniting Forces: Leveraging Cancer Research to Revolutionize Tuberculosis Treatment
World - first lung cancer vaccine trials launched across 7 countries
Facebook
RSS Feed
X
Linkedin
Youtube